摘要目的 观察吡格列酮对2型糖尿病患者氧化低密度脂蛋白(OXLDL)的影响并探讨其可能的发生机制.方法 选择符合WHO 1999年诊断标准的2型糖尿病患者65例,随机分成治疗组(33例)和对照组(32例).治疗组降糖药物选用胰岛素或磺脲类+吡格列酮,对照组仅用胰岛素或磺脲类控制血糖,其他常规治疗药物中不使用二甲双胍、血管转换酶抑制剂、阿斯匹林、他汀类、维生素C、维生素E等药物.疗程6个月.所有患者治疗前后均于清晨空腹抽血留取标本,用于氧化低密度脂蛋白(OXLDL)的测定.结果 65例患者共有61例完成了本观察,两组患者治疗后OXLDL较治疗前明显降低(P均＜0.05)；治疗后治疗组OXLDL下降水平明显高于对照组(P＜0.O1).治疗中无一例患者出现明显不良反应.结论 吡格列酮除具有降血糖作用,同样具有降低糖尿病患者血中OXLDL水平,改善2型糖尿病患者抗动脉粥样硬化的能力.

abstractsObjective To observe the effect of pioglitazone on oxidized low-density lipoproteins (OXLDL) in type 2 diabetes patients and investigate the possible mechanism.Methods Sixty-five patients with type 2 diabetes mellitus who in accord with diagnostic criteria of WH0 1990 were randomly divided into therapy group ( n =33) and control group ( n =32).Choose insulin or sulphanylureas with or without pioglitazone as therapy drug The therapy course was 6 months.Changes of OXLDL of fasting blood were observed in the therapy group and the control group before and after the trial.Results Sixty-one cases completed this obervation.The level of OXLDL of fasting blood decreased obviously after treatment both in therapy group and control group( all P ＜ 0.05).The level of OXLDL of fasting blood of therapy group decreased more obviously than control group after treatment( (P ＜ 0.01).There was no patient with obviously adverse reaction.Conclusions Pioglitazone has the effect of hypoglycemia and decrease serum OXLDL level,improve the antiartherosclerosis ability of type 2 diabetes mellitus patients.